Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Kymera Therapeutics has closed its second sizable financing round, securing $65 million from a syndicate of investors co-led by 6 Dimensions Capital, Bessemer Venture Partners, and Pfizer Ventures. Kymera, which was one of C&EN’s 10 Start-Ups to Watch this year, was founded in 2016 to develop protein degraders, complex small molecules that tag an errant protein for the cellular trash bin. The company, which has now raised nearly $100 million, expects to put its first drug into human tests in 2020.
This article has been sent to the following recipient: